TheraRadar
← Back
Data updated: Mar 29, 2026

HENGRUI PHARMA

OncologyRespiratoryDermatology
Generics

HENGRUI PHARMA is a generic drug manufacturer focused on Oncology, Respiratory, Dermatology.

2011
Since
17
Drugs
-
Trials
100
Approved (2yr)

Key Drugs

CISATRACURIUM BESYLATE PRESERVATIVE FREE
cisatracurium besylate
cholinergic receptor · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

DEXMEDETOMIDINE HYDROCHLORIDE 2026-02-17
Labeling
DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
OXALIPLATIN 2026-01-15
CISATRACURIUM BESYLATE 2025-11-03
Labeling
OXALIPLATIN 2025-10-22
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 43%
4 drugs Phase 3: 2 Phase 2: 4 Phase 1: 23
Respiratory 23%
1 drugs Phase 3: 2 Phase 2: 5 Phase 1: 9
Dermatology 16%
1 drugs Phase 3: 2 Phase 2: 4 Phase 1: 2
Immunology 10%
0 drugs Phase 2: 5 Phase 1: 4
Infectious Disease 8%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology
GSK big-pharma
Infectious Disease, Respiratory, Oncology, Immunology
Sanofi big-pharma
Oncology, Infectious Disease, Immunology, Respiratory
COSETTE other
Dermatology, Infectious Disease, Immunology, Oncology
Novartis big-pharma
Oncology, Immunology, Respiratory